Born in Switzerland during the posting of his British parents with the British Consulate General in Zurich, he went through his schooling in Switzerland and initially studied Veterinary medicine at the University of Zurich, obtaining his diploma as veterinary surgeon and Doctor of Veterinary Medicine in 1982. His first PhD entitled “Parathyroid cell variants may be provoked during immersion fixation” was done in 1987 and earned him Fellow of the Royal Microscopical Society FRMS. After studying Comparative Ophthalmology, resulting in a second PhD thesis and his Doctor title from the University of Zurich on “Mesodermal Goniodysgenesis in the Siberian Husky”, he started work at Dispersa AG, later Ciba Vision Ophthalmics and Novartis Ophthalmics as a medical consultant, drugs regulatory affair and later becoming Vice President and responsible head of Medical Affairs. During this time, he developed his first interests in stem cells, leading to research projects into adults mesenchymal stem cells from bone marrow and adipose tissue to treat ophthalmic conditions such as AMD, Keratoconjunctivitis sicca and glaucoma. He then set up his own company, Med Cell Europe, where first treatment of stem cell transplants, GMP conform production methods and a whole range of research was performed. This lead to one of the first treatment and stem cell laboratories in Switzerland, several patents on the production of exosomes and paracrine substances by mesenchymal stem cells and the development of treatments with Dendritic Cells, the successful transformation of mesenchymal stem cells into dopamine and insulin producing cells. Dr Kellner is now founder and chief scientist of Mesencell Biotech, which focuses on autologous stem cell and dendritic cell treatments in the Middle East and Northern Africa, co-founder and chief scientist of Med Cell Bahamas with a government licence for stem cell treatments in the Bahamas, co-founder and chief scientist of Med Cell International in the USA and co-founder, board member and chief scientist of Med Cell plc responsible for worldwide research projects and clinical trials for diseases such as Alzheimer Disease, Parkinson Disease, Diabetes T1 and T2 and osteoarthritis. Apart from his main research focus into neurological disease (Alzheimer and Parkinson Disease and retinal disease) Dr Kellner mentors young biotech start-up companies and actively seeks and finds collaboration with other research institutes and local governments.

Mesenchymal Stem Cells: Increasing neurotrophic substances in the secretome produced by mesenchymal stem cells (MSCs), Treatment of Alzheimer Disease with MSCs, Treatment of Parkinson Disease with Dopamine producing cells, Treatment of Age related macular degeneration with MSCs. Dendritic Cells: Treatment of Multiple Sclerosis, prostate cancer, cancer prevention Biomarkers: Development of biomarkers for the diagnosis and monitoring of Alzheimer Disease, Parkinson Disease, osteoarthritis and ageing/morbidity Other Cells: transfected MSCs, induced pluripotent stem cells, olfactory ensheathing cells, MUSE cells

Tetsuro Tamaki completed undergraduate training in physical education at the Waseda University of Tokyo in Japan prior to obtaining an MS degree in physical education (Exercise Physiology) and a PhD degree in Medicine(Physiology) from the Tokai University of Kanagawa in Japan. He has held faculty positions in the Department of Physiology at the Tokai University School of Medicine of Isehara in Kanagawa. He is currently an associate professor in the Department of Regenerative Medicine, Division of Basic Clinical Science, Tokai University School of Medicine, and the head of the laboratory of the muscle physiology and cell biology unit. He is involved in experiments focused on skeletal muscle hypertrophy, hyperplasia, regeneration and aging on the basis of neuromuscular physiology. Recently, he has mainly been involved stem cell biology and therapy using skeletal muscle interstitium-derived multipotent stem cells. Currently, his study is extending the cross-talking among hypertrophy, hyperplasia, regeneration and aging and stem cells in the skeletal muscle.

skeletal muscle interstitium, adult stem cells, regenerative medicine, stem cell therapy, cardiomyocyte, peripheral nervous system, nerve regeneration.

Prof. Yong Li completed his medical education and Ph.D. training in China. He went to the Imperial College in London for his 1st postdoc fellowship, then he started his 2nd postdoc associated job in the Children's Hospital of Pittsburgh. He was promoted to a tenure track Assistant Professor within Orthopedics, Pathology, and Bioengineering of the University of Pittsburgh in 2005. He appointed as Associate Professor of Center Stem Cell for Regenerative Medicine and Pediatric, Orthopedic and Internal Medine of University of Texas Medical School at Houston in 2011. Dr. Li has more than one hundred peer-reviewed publication and his team is well-founded through DOD and NIH grants. He owns twenty national and international awards, including the Michael Miller Young Investigator Award from UPMC. He also was a student mentor of National Goldwater scholarship.

Adult stem cells and niche factors, stem cell motivation, stem cells and angiogenesis in natural aging, genetic and epigenetic regulations in stem cells, cancer stem cell, translational studies.

Born and raised in Mallorca, Spain, Dr. Llull obtained his medical degree with honors at University of Navarra, Spain in 1988. Awarded a Fulbright-Hyes Commission Scholarship, he moved to California to undertake his doctoral studies at University of California, Irvine. He received his PhD degree in cell biology and Immunology in 1992. His research on the immunological aspects of musculoskeletal tissue transplantation received the Henry Christian Memorial Award (1991) for Excellence in Research from the Association of American Physicians and was sponsored by the Plastic Surgery Educational Foundation and the American Association for Hand Surgery. Following a research post-doctoral year at the Thomas E. Starzl Transplantation Institute and a microsurgical fellowship at the Division of Plastic Surgery in Pittsburgh, Dr. Llull obtained a Diplomate from the European College of Transplantation. He subsequently entered a plastic surgery clinical training at the University of Pittsburgh residency program. During his training was awarded the 1994 young investigator award from the International Transplantation Society and awards by the ASPS and the PSEF. Dr. Llull actively participated in the Pittsburgh’s Tissue Engineering Initiative on several tissue engineering projects related to cell and developmental biology of soft tissues, specifically adipose tissue. He has co-authored more than 30 scientific publications, holds several US and international patents related to cell related biotechnology and conceived, designed and validated devices, reagents and processes, all related to surgical cell therapy. Clinically, he served as staff surgeon both at Clinica Planas and Hospital del Mar in Barcelona until 2002, when he was appointed Chief of Plastic and Reconstructive Surgery at the MD Anderson Cancer Center, in Madrid, Spain until 2009. Since then, Dr. Llull directs the Stem Europe Center in Mallorca, Spain, where he combines his practice with a Cell Therapy Translational and Clinical Research Center. At Stem Europe Mallorca Center his team designs and executes clinical trials related to tissue engraftment and neogenesis for reconstructive and cosmetic indications and provides training and educational support for technology early adoption (www.stem-europe.com) Dr. Llull is a founding member of Cell Source (currently Cytori), The GID Group, Ltd, and is a Scientific Board Member of Antria, ClusterXStem and others. He is proud to be a founding member and First President of the International Federation for Adipose Therapeutics and Science (IFATS), consults for various biotech companies like Biotime, and despite all that, he remains a passionate physician, a wannabe painter, a lazy sailor, and a shy poet.

The role of stroma-derived Stem cells Cellular and subcellular mechanisms of progenitor-to-terminally differentiated cells and its therapeutic benefits, The concept of healing parenchyme with mesenchyme

Dr. Xuejun Huang Parsons received her BS in Biology from Fudan University, PhD in Biochemistry, Molecular, and Cell Biology from Cornell University, and completed her PostDoc studies as a Leukemia and Lymphoma Society Research Fellow at University of California at San Diego, USA. Since, she has been supported by grants from National Institutes of Health (NIH) to become an independent stem cell scientist and leader in pluripotent human stem cell research as principal investigator and faculty at University of California and Sanford Burnham Medical Research Institute, USA. She has served as the key personnel and project leader in one of the US exploratory centers for pluripotent human stem cell research funded by National Institutes of Health (NIH), and has led the collaborative effort with prestigious US stem cell biologists to develop the utility of pluripotent human stem cells as a model system for a diverse range of biological and medical problems. Dr. Parsons is the co-founder and President of San Diego Regenerative Medicine Institute, founder and CEO of Xcelthera INC, and co-founder and CEO of PluriStem Biopharmaceutical Ltd. Dr. Parsons is an internationally recognized expert and leader in the emerging field of pluripotent human stem cells and regenerative medicine, and has been invited to speak at many international conferences on stem cells, regenerative medicine, and cell therapy. Dr. Parsons' invention on pluripotent human stem cell technology has won prestigious North American Technology Innovation Award in Stem Cell Technologies in 2013 based on an extensive and independent competitive analysis of the North American Stem Cell Technologies Market and the findings of Best Practices research by Frost & Sullivan. Dr. Parsons is the inventor of several patents on human stem cell technology, author of more than 20 high impact articles published in internationally-recognized top scientific journals of stem cells and regenerative medicine, and serving on the editorial boards of several open-access scientific journals. Dr. Parsons has many years of experience in biomedical research and life sciences industry, with expertise and leadership in human stem cell research and cell-based regenerative medicine, in-depth understanding of pluripotent human stem cell research to the advance of medicine and improvement of human health, and entrepreneurship in business startup. Her original human stem cell research breakthroughs render high efficient neuronal or cardiac lineage-specific differentiation directly from the pluripotent state of human embryonic stem cells by small molecule induction, which opens the door for human neural and cardiac tissue engineering and regeneration as well as to investigate molecular neurogenesis and cardiogenesis in human embryonic development using powerful in vitro model systems. She is the first to develop the proprietary breakthrough human stem cell technology for large-scale production of high quality clinical-grade pluripotent human stem cell lines and their functional human neuronal and heart cell therapy derivatives for commercial and therapeutic uses, which have overcome some major obstacles in bringing pluripotent human embryonic stem cell therapy derivatives towards clinical applications for unmet medical challenges in incurable or hitherto untreatable neurodegenerative and heart diseases, and which has generated intellectual property to enable therapeutic development, commercialization, and clinical practice of proprietary pluripotent human stem cell therapy tools and products for startup company. Her medical innovations provide life scientists and clinicians with novel, efficient, and powerful resources and tools to address world-wide major health concerns, which will shape the future of medicine by providing pluripotent human stem cell-based technology for human tissue and function restoration, and bringing new therapeutics into the market.

stem cell research, regenerative medicine, cell therapy, neural regeneration/engineering, cardiac regeneration/engineering, cellular and molecular medicine

A/Professor Sidhu has more than 28 years of experience in the major field of reproductive technology with specialisation in cell and developmental biology including stem cells discovery and transitional research, administration, management and liaising with industry partners. To date, he has produced two international patents on human embryonic stem cells, and in 2010, filed another application for a patent for producing the first disease-specific induced pluripotent stem cell clones that are the resource material for NHMRC Development Grant Application under consideration. Earlier in 2008 he produced a high throughput neural chip for protein expression analyses in collaboration with a biotech company.

Pluripotent Stem Cells

Dr. Christoph Schaniel in 2007-06/2008 appointed as Instructor in Department of Gene and Cell Medicine, and The Black Family Stem Cell Institute, Mount Sinai School of Medicine, New York, NY In 2008-05/2011 Assistant Professor (Research track) Department of Gene and Cell Medicine, and The Black Family Stem Cell Institute, Mount Sinai School of Medicine, New York, NY In 2011-11/2012 Assistant Professor (Research track) Department of Developmental and Regenerative Biology, and The Black Family Stem Cell Institute, Mount Sinai School of Medicine, New York, NY In 2012-present Assistant Professor (Investigator track, primary appointment) Department of Pharmacology and Systems Therapeutics, and The Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY 1/2014-present Assistant Professor (Investigator track, secondary appointment) Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, NY

The discovery that specialized, adult somatic cells when exposed to pluripotency-associated factors or microRNAs (miRs), can become plastic and regain embryonic stem cell (ESC) characteristics was a groundbreaking advance in stem cell research. This induced pluripotent stem cell (iPSC) technology, especially when applied to patient-samples, has brought great excitement because it generates an unlimited source of cells capable of differentiation to any cell type, to model human diseases in a dish, to understand underpinning mechanism(s) in a disease-relevant cell-context, to develop diagnostics and novel (personalized) therapeutic strategies and to test a drug’s efficacy and adverse effects by a “clinical trial in a dish”.

Dr. Keller was recruited to the University of Louisville School of Medicine as the Kosair Charities Chair and Director of Pediatric Heart Research in the Cardiovascular Innovation Institute and senior member of the Division of Pediatric Cardiology, which provides congenital heart care to children and adults with acquired pediatric and congenital heart disease. Dr. Keller provides both outpatient and inpatient pediatric cardiology subspecialty care. Dr. Keller also serves a leadership role within the Department of Pediatrics as the Vice Chair for Research.

Cardiovascular Developmental Biology, Biomechanics, Tissue Engineering, Stem Cells applied to the cardiovascular system.

Dr. Hassan Azari has received his PhD from Medical University of Isfahan (MUI) in the field of anatomical sciences- stem cell biology. Currently, he is working as an assistant professor in Shiraz University of Medical Sciences (SUMS). He has successfully established Shiraz Stem Cell Institute (SSCI) in year 2012 and currently serves as the executive director of SSCI. His primary research interests include neural stem cell biology and it's applications in regenerative neuroscience. He is also interested in brain tumor biology and therapy. He is serving as an editorial member of several reputed journals like Frontiers in Neurotrauma & Journal of Stem Cell Research and Therapy, and expert reviewer for journals like Science Reports, Journal of Neuroscience Research and Journal of Visualized Experiments. He has published more than 25 papers in peer-reviewed journals and is an author of 3-book chapter.

1. Neural Stem Cells Biology 2. Neural Cancer Stem cell Biology 3. Embryonic and Induced Pluripotent Stem Cells Biology (Neural differentiation) 4. Cell Replacement Therapy of Neurological Diseases 5. Development of new technologies for neural cell selection and Isolation 6. Immunotherapy of brain cancers

Prof. Masato Sato is the member of Japanese Orthopedic Association. From 2012 till date he is the Director, Research Source Bank, Tokai University, School of Medicine. From 2010 till date he is the active Director, Cell Processing Center, Tokai University Hospital.

Orthopaedic Surgery,Rheumatology, Spinal Surgery, Laser Surgery.

Graduated Toho University Medical School at Tokyo in Japan on March 31th 1978 Passed the Japanese National Board Medical Examination on May 1978 Worked research fellow in Department of Neurology, Baylor College of Medicine, in Houston under Dr. Appel in USA between October 1984 and October 1986 Assistant professor of Neurology, Toho University Ohashi Hospital from April 1991 and associate professor of Neurology, Toho University Ohashi Hospital on April 1997 and became Professor and Chairman in Department of Neurology Toho University Omori Hospital from April 2005 and present time.

Neurodegenerative disorders, especially amyotrophic lateral sclerosis.

Dr. Xu received her Ph.D. in China Medical University in 2009 and completed her postdoc training in the role of stem cells in metal carcinogenesis in the laboratory of National Toxicology Program (NTP) at National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH) in 2013. She is currently a professor in School of Public Health, China Medical University. She is author /coauthor of over 30 peer-reviewed scientific papers.

Cancer stem cells, redox homeostasis and stem cell differentiation

Scientific advisor for Veterinaria Italiana

Stem Cell Research

Editorial Board of the Journal of Basic Medical Sciences of Iran (JBMSI) Pharmaceutical Biotechnology board of examination, Ministry of Health, IRAN Editorial Board of the Medical Biotechnology Research (MBR)

Pharmaceutical Biotechnology

A. Administrative Job: Acting Chairman, department of Orthopaedic surgery, on number of occasions. Coordinator, Department Research Committee. B. Committee Membership: Coordinator of Postgraduate academic activities, since 1988-2002. Member, Infection control committee, 1992. Coordinator Undergraduate rotations and teaching, 1992. Coordinator, Saudi/Arab Board Residents in Orthopaedic Training Program. Member Research Committee, College of Medicine, University of Dammam.

1. Metabolic Bone Disease: Osteoporosis, Osteomalacia and Vitamin D Deficiency 2. Arthritis: Hips and Knee Arthroplasty. 3. Major Trauma 4. Orthopaedic Oncology. 5.Stem Cell Therapy for Avascular Necrosis of femur and Humerus and Osteoarthritis of Knee.

Member of Human Tissue Committee in China, Member of 13th 5-year Biomedical development planning Committee, China, Member of Drug Review Committee of CFDA, China, Member of Physiology Society, China, Member of Physiology Society, UK, Member of High Education Strategic Research Committee, China, Key Panel Member of Biomedical Industry Investment committee of Xiangshui County, Member of Economic and Industry Development Committee of Jiangyin County, Member of assessor committee for NSF.

My current research falls into 5 related programs. 1) Physiology role of carbon monoxide (CO) and its mechanism; 2) studying ion channels and receptors in the mitochondria; 3) other functions of ion channels; 4) pulmonary hypertension and stenosis; 5) Immune cell engineering toward cell therapies. Some directions are the extension of my previous work but most of works are closely around ion channel study and cardiovascular diseases.

Prof. Khaled Radad finished his undergraduate study at the Faculty of Veterinary Medicine, Assiut University, Assiut, Egypt in 1993. In 1998, he finished his master degree in the branch of toxicological pathology. He started his Ph.D. study in the Institute of Medical Chemistry, Department for Biomedical Sciences, University of Veterinary Medicine Vienna, Austria in the field of neurobiology in 2001. After graduation in 2005, he returned back to his home country and worked as assistant professor of pathology at the Department of Pathology, Faculty of Veterinary Medicine, Assiut University, Assiut, Egypt. Since 2008, he is working as professor of pathology at the Department of Pathology, College of Medicine, King Khalid University, Abha, Saudi Arabia. He is teaching general pathology for dentistry undergraduate students. Beside teaching duties, he is involved in research activities in the fields of toxicological pathology and neurobiology.

Regenerative medicine, neuronal cell research, neuronal degenerative/regenerative research, cellular and molecular medicine, toxicopathological research

Dr. Ying-Fu Chen is a Professor of Surgery, and Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. He has a MD degree from Kaohsiung Medical College, Kaohsiung, Taiwan, in 1973, and his PhD degree from Graduate Institute of Medicine, Kaohsiung Medical University, in 1992. In 1983, Dr Chen was as a clinical fellow at the Heart Institute of Japan, Tokyo Women Medical University. In 1985, he went to Durham, North Carolina, as a research fellow at Duke University Medical Center. In 1992, Dr Chen was appointed as Professor of Surgery at Kaohsiung Medical University. He is also appointed as a Professor of Graduate Institute of Medicine, Kaohsiung Medical University. His main research interests include inflammation, vascular degeneration, and stem cells in basic studies and thoracic aorta aneurysms/dissections and aortic valve diseases in clinical fields. He has authored over 80 peer-reviewed medical publications and has served as editorships of 2 books, authorships of many book chapters. Currently, He is also as an editorial member of many national and international journals.

1. Ischemic Heart Disease Coronary Artery Bypass Grafting 2. Valvular Heart Disease Mechanical Valve vs. Bioprosthetic Valve Transcatheter Valve Replacement Aortic Valve Disease Bicuspid Aortic Valve Disease 3. Atherosclerosis and Statin Therapy 4. Cellular and Molecular Mechenisms of Thoracic Aortic Aneurysms/Dissections 5. Acute Aortic Syndrome Aortic Dissection and Endovascular Repair 6. Anticoagulants and Antiplatelet Therapy VKA-OACs (Vitamin K antagonist Oral Anticoagulants) NOACs (Novel Oral Anticoagulants) Antiplatelet Therapy 7. Congenital Heart Disease Congenital Coronary Anomaly 8. Thoracic Aortic Aneurysms/Dissections Aortic Root Replacement and Total Arch Replacement TEVAR (Thoracic Endovascular Aortic Repair) 9. Congestive Heart Failure Cardiac Remodeling 10. Stem Cells and Cardiac Regeneration

Prof. Yoo-Hun Suh is now Chaired Professor and President of the Neuroscience Research Institute of Gachon Univ. He was the founding president of Korea Brain Research Institute. Furthermore, he is a professor emeritus of College of Medicine at Seoul National University. He won Korea’s Most Distinguished Scientist Award, the National Government Medals and other many prizes. He was selected one of 20 outstanding Korean Medical Scientists and one of 21 outstanding Korean Scholars of the 21st Century. He is an editor and editorial board member for 6 SCIs (Journal of Pharmacological Sciences, Journal of Neurochemistry, Journal of Molecular Neuroscience, Journal of Neuroscience Research, Neurochemical Research and Neuroscience Research). He first cloned the gene for epinephrine synthesizing enzyme, PNMT and has greatly contributed to the discovery of a new potential gene and factors for AD, the development of potential stem cell and drugs for AD and PD. He has published more than 200 papers and over 50 books. Presently, professor Yoo-Hun, Suh is a Member of Board of Trustee, HFSP(Human Frontier Science Program), a member of Korean National Academy of Science and Technology, a member of Korean National Academy of Medicine and a Member of Korean National Science and Technology council. In addition, he is a Member of International Scientific Advisory Board of AD & PD and a Member of International Scientific Advisory Board of International Conference of Alzheimer’s Disease and related disorders(AAIC). He was the chairman of the Organizing Committee of the 22nd Biennial Meeting of international society of neurochemistry(ISN), the president of FAONS(Federation of Asia, Oceanic Neuroscience Societies), the president of APSN(Asia Pacific Society for Neurochemistry), the president of Korean Society for pharmacology, the president of Korean Society for Brain & Neuroscience, the president of Korean Society for cognitive Science, the president of Korean Society for neurodegenerative Diseases, the president of Korean Mind, Brain and Education Society, the Director of National Creative Research Initiatives Center for AD, the Director of Neuroscience Res. Institute, Seoul National Univ. and the Director of Cognitive Science Inst., Seoul National Univ..

Pathogenesis, Early diagnosis and Stemcell therapy for AD, PD and other brain diseases.

1989-1991 Dipartamento di Farmacologia. Universita degli Studi di Milano (Italy) 1992 Cell Biology and Genetics Program. Memorial Sloan-Kettering Cancer Center. New York (USA) 2001 Unité 344 Endocrinologie Moleculare Inserm. París (Francia) CURRENT POSITION Profesor Titular and Head of Department Department of Physiology. Universidade de Santiago de Compostela

Neurophysiology, Neuroendocrinology, Neurodevelopment,Cancer

Graduating in Biology from the Universidad de Granada (Spain), Amancio Carnero began his scientific career in the Genetics Department at the same University where he spent two years as an undergraduate student. He then moved to the Instituto de Investigaciones Biomédicas “Alberto Sols”, CSIC, Madrid and carried out his PhD studies at the Department of Molecular Biology at the Universidad Autónoma de Madrid. Amancio Carnero worked on the signal transduction mechanisms induced by Ras oncogenes. He found that Ras activates a Phopholipase D and that the results of such activation have a role in mitogenesis. Upon completing his PhD in 1994 he was an Associate Professor at the Department of Biochemistry, the Universidad Autónoma de Madrid, from where he moved in January 1996 to the Cold Spring Harbor Laboratory, New York, USA, as a Postdoc in the laboratory of D. H. Beach. When D. Beach’s lab moved to London, Amancio returned to Europe as a Senior Research Fellow at the Institute of Child Health and Great Ormond Street Hospital, University College London (UCL), UK where he worked to improve methods for identifying new molecular targets based on functional screenings (either by gain or loss-of-function). His research interests focused on the cell cycle, cellular senescense and cellular immortalisation. He then spent another two years in London at the Wolfson Institute for Biomedical Research (UCL) as a Senior Lecturer before returning to Spain in 2001 to assume his current position as Head of the CNIO’s Assay Development Section in the Experimental Therapeutics Programme. During 9 years He worked at the CNIO developing the preclinical platform to identify new antitumor therapies. At the end of 2009, Amancio move to the Institut of biomedicine of Seville were He followed his work in The identification and characterization of genes with therapeutic relevance in cancer, Establishing the causality during tumor initiation and progression, Validation of new therapeutic targets.

The research lines in this laboratory are: • Identification and characterization of genes with therapeutic relevance in cancer. • Establishing causality in the initiation and progression of the tumoral process. • Validation of new therapeutic targets that could form the basis for the identification of new anti-tumor compounds.

DATES POSITION ORGANISM 1964-1970 Intern alumn, Dpt. of Physiology. University of Santiago 1970-74 Associated Professor, Dpt. of Physiology University of Santiago 1973-74 Special Prof. of Physiology and Biochemistry University of Granada 1974-1993 Special Prof. of Physiology and Biochemistry University of Santiago 1993-2012 Professor of Physiology University of Santiago 1975-2012 Head of the Lab of Special Biochemistry University Hospital 1975- Supervisor of Radioactive Instalations 2012-2015 Profesor "Ad Honorem" Universidad de Santiago 2012- .... Scientific Director Foudation and Medical

Growth Hormone and stem cells, IGF-I, medical therapies for neurorehabilitation.

Sergey Suchkov was born in the City of Astrakhan, Russia, in a family of dynasty medical doctors. In 1980, Suchkov graduated from Astrakhan State Medical University and was awarded with MD. During the studentship Suchkov was extensively involved into research in the area of ocular immunology and won in 1980 the First Prize at the First International Contest among the Medical Students in Praque. In 1985, Suchkov maintained his PhD as a PhD student of the I.M. Sechenov Moscow Medical Academy and Institute of Medical Enzymology, USSR Academy of Medical Sciences, Moscow, Rus-sia. In 2001, Suchkov finished the PostDoc Research Fellowship Program and maintained his Doctor Degree at the National Institute of Immunology, Russia. From 1985 through 1987, Dr Suchkov worked as a Post Doc Research Associate, Department of Medi-cal Biotechnology, Institute of Medical Enzymology, USSR Academy of Medical Sciences to be in-volved into research in clinical enzymology and applications of DNA-dependent enzymes in clinical medicine. From 1987 through 1989, Dr Suchkov was a senior Researcher, Lab of Developmental Immunology, Koltzov Institute of Developmental Biology, USSR Academy of Sciences to deal to developmental immunology. From 1989 through 1995, Dr Suchkov was being a Head of the Lab of Clinical Immunology and Im-munobiotechnology, Helmholtz Eye Research Institute in Moscow. From 1995 through 2004, Dr Suchkov was being a Chairman of the Dept for Clinical Immunology, Moscow Clinical Research Institute (MONIKI) and the Immunologist-in-Chief of the Moscow Regional Ministry of Health.

Immunlogy and Immunogenetics, Translational Medicine, Personalized medicine, Molecular and Cellular Biomarkers Targeting

Strategic Objectives Molecular characterisation of CNS neoplasms. Characterisation of the tumour stem cell population in Glioblastoma Multiforme (GBM). Analysis of the diagnostic and prognostic value of different immunohistochemical and molecular markers on CNS neoplasms.

Cancer, Neuro-oncology, stem cells, tumor suppression, Sox genes, aging,

Academic Title： Young Committee Member, Endocrine Society of Jiangsu Province, China Member of Study Group, Endocrine Society of Jiangsu Province, China Committee Member, Suzhou Endocrine Society, China Member of the International Chinese Musculoskeletal Research Society (ICMRS) Work Experience: As Physician since 1998, Dept. of Endocrinology, The 1st Affiliated Hosp. of Soochow University Education and Training： 1992-1998 China Medical University, Bachelor’s degree of Medicine 2001-2004 Tongji University, Master’s degree of Medicine 2007-2010 Shanghai Jiaotong University, Doctor’s degree of Medicine 2008-2009 ANZAC Research Institute, Sydney University, Combined-education supported by China Scholarship Council(CSC)

Clinical Genetics; Inherited Metabolic Diseases; Disorders of Sex Development; Stem Cell Differentiation and Development; Osteoblast; non-coding RNA

Ssang-Goo Cho received B.S., M.S., and Ph.D. degrees in Genetic Engineering from Korea University, Republic of Korea. He was awarded a postdoctoral fellowship at Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, USA and worked at Korea University as a research professor and at Institut Pasteur as a visiting scientist. Now, he has been serving as a professor at the department of Stem Cell & Regenerative Biotechnology, Konkuk University and also as a director of Incurable disease animal model and stem cell institute (IDASI). His areas of expertise include signaling pathways in stem, cancer, and cancer stem cells, molecular mechanism of cellular reprogramming, and apoptosis or autophagy, pancreatic beta-cell differentiation. He has published more than 130 papers in scientific journals.

Signaling pathways in stem, cancer, and cancer stem cells, Molecular mechanism of cellular reprogramming, Apoptosis and autophagy, Cancer stem cells, induced pluripotent stem cells, Pancreatic beta-cell differentiation, Pancreatic cancer cells.

2003-2007, Ph.D. Molecular Genetics, Faculty of Basic Science, Tarbiat Modares Univercity Thesis Title: Comparative Study and Interfering in Expression Profile of Neurotrophins, their Receptors and Prohormone Convertases Genes in Rat Bone Marrow Stromal Cells and Spinal Cord- Nerve Injury Tissues 2003-2008, M.Sc. Molecular Genetics, Faculty of Basic Science, Tarbiat Modares Univercity Thesis title: The Molecular Identification of the most Prevalent Mutations of Glucose-6-Phosphat Dehydrogenase (G6PD) Gene in Deficient Patients in State of Gilan 1996-1999: B.Sc. Biology, Faculty of Basic Science Shahid Beheshti University

1- Khwarizmi international award for technical knowledge of biological capsule carrying a monkey into space and return 2- National Elite foundation awards for Generating genetically engineered bone marrow stromal stem cells with reduced rate of cell death after induction 3- Presidential award in national festival of innovation 4- Letter of appreciation from presidential of IR.IRAN for space capsule and associated rocket, Pishgam (Pishgam: space monkey) 5- Letter of appreciation from Vice president for space capsule and associated rocket, Pazhuhesh (Fargam: space monkey) 6- Letter of appreciation from Deputy Minister of Ministry of Science, Research and Technology of IR.IRAN for Biological capsule in national space lab #3 (Kavoshgar-3) 7- Letter of appreciation from head of Iran Space Agency for Biological capsule in national space lab #4 (Kavoshgar-4) 8- Letter of appreciation from head of Iran Space Agency for space capsule and associated rocket, Pishgam

Prof. Yong Sang Song received his doctor’s degree from Seoul National University, Korea in 1983. He worked in Unviersity of Wyoming, Laramie, as research fellow in Department of Molecular Biology in 1997, and then as associate Professor from 2001 to 2005. He set down and became professor and associate dean of College of Medicine Seoul National University Department of Obstetrics/Gynecology and he was elected as chairman of Korean Society of Urogynecology in 2006. And in 2009 he was selected as director of Cancer Research Institute in 2009 in Seoul National University. In 2009, he also organized International Conference of NAPA and was selected as chairman of Asian Society of Gynecologic Oncology (ASGO) Scientific Committee. In 2012 he was selected as president of Korean Society of Cancer Prevention. His major interests are molecular mechanisms of tumors, especially the role of tumor microenvironment in cancer cell metabolism and chemoresistance and precision medicine in ovarian cancer. He is particularly interested in the impacts of components of tumor microenvironment in ovarian cancer progression. He has published more than 300 papers in the science citation index (SCI) journals such as BMC cancer, Molecular Carcinogenesis, Cancer Letters, Oncotarget etc. He has received the prize of Scientific Paper, Korean Scientific Association, Grand prize, Korean Society of Colposcopy and Gynecologic Oncology, Academic award, International Conference on Ovarian Cancer, President Award on Prevention in Korean Government and Boryung Cancer Academic Award on Prevention in Korea. He is also the editor in chief and senior editor or member of editorial board of scientific journals, such as International Journal of Clinical Medicine, Journal of Cancer Prevention, Cancer Letters and Molecular Carcinogenesis.

Precision medicine in ovarian cancer, tumor microenvironment, cancer cell metabolism, chemoresistance

Co-author of more than 90 publications in international journals, on the role of purines at the central nervous system, in particular on glial activities such as proliferation, neuroprotection and neuro/pleiotrophin production. The study is now addressing also the characterization of mesenchymal stem cells from normal human tissues (dental pulp and dental papilla, amniotic fluid, adipose tissue) and tumors (glioblastoma multiforme) and the role of purine on osteogenic and adipogenic differentiation of some of the above mentioned normal cells and on the survival of those of tumor derivation.

Reviewer for international journals both in the field of Regenerative Medicine (Tissue Engin., Differentiation, Stem Cell Int., Stem Cells Rev. Rep., PlosOne) and Neuropharmacology (Purinergic Signaling, Mol. Neurobiol., Int. J. Develop Neurosci, J. Neurochem, Neuroscience, etc.). She has been funded as Head of Operations Unit at previous PRIN (1999, National Coordinator: Prof. F. Nicoletti, 2003, National Coordinator: Prof. G. De Sarro, 2008, started in 2010, National Coordinator: Prof. PL. Canonico); each research has been published in relevant articles.

GULIK Drs Elisabeth Thecla Maria van der, Retired Physician. Personal: Born 19 December 1947, Amsterdam, The Netherlands. Education: Analytical Chemist, Westeinde Hospital, The Hague, 1967-69; MD, Catholic University, Nijmegen, 1969-80; Course in General and Experimental Oncology, Institute ARC, Villejuif, France, 1985-86; Assessment Medicine, SMI course, School of Public Health, Utrecht, 1999; Course of Counselling and Coaching, Benelux University Centre, Eindhoven, Netherlands, 2002-05. Positions held: Assistant pathologist, clinical and research departments, Amsterdam, Paris, Brussels, 1980-1988; Physician, Bureau of Driving Licenses, Rijswijk, The Netherlands, 1990-1992; Physician of Assurance Medicine, GUO, GAK, ZVN, 1992-99; Physician of Occupational Health, several Arbo Services, 1999-2012. Retired from practice as a physician, 2012 -. Honours: Decree of Merit, World Who’s Who of Women, IBC, 1997; Award of Excellence, ABI-IBC, International Congress, 1998; Hall of Fame, International Who’s Who of Professional and Business Women, 6th edition, ABI, 1999; ABI-IBC Congress Medal, 2000; Outstanding Artistic Performance, ABI-IBC, International Congress, 2000, 2001, 2002, 2004, 2005, 2006, 2007, 2008, 2012; Achievement of Merit in Music, International Congress IBC, 2014, 2015; Hall of Fame, IBC, 2007; other awards, positions and listings ABI/IBC. Memberships: Dutch Royal Academy of Medicine, Utrecht, 1978-; Association of “Friends of the Song”, Amsterdam, 2000-.

Actual health care, and related problems in different fields: molecular biology, databases, medical legislation, ethical problems and health care, sustainability, preventive, predictive and personalized Medicine (PPPM).

Dr. Gabriel Lopez-Berestein is a Professor in the Department of Experimental Therapeutics at MD Anderson Cancer Center (MDACC) and served as the Executive Director of the MDACC Pharmaceutical Development Center. He is internationally known for his research pertaining to development of nanomedical applications that has resulted in more than 200 patents and clinical trials and the FDA-approved drug, Abelcet™ (liposomal amphotericin-B), which is available worldwide and considered standard treatment for life-threatening fungal infections. For the last 30 years Dr. Lopez-Berestein has been studying different aspects of cell death and differentiation and cell signaling.

Immunology, Internal Medicine, Oncology-Developmental Therapeutics

Clinical and Research Investigator at Department of Basic Medical Sciences, Neurosciences and Sense Organs, School of Medicine - University of Bari ALDO MORO. Dental Medicine Doctor (University of Bari ALDO MORO, Italy), Master of Science (M.Sc.) in Orthognathodontics (University of Foggia, Italy) and in Sexuality Medicine (University of Bari ALDO MORO, Italy). Post-Graduate in Epidemiological Methodology, Bioethics, Culture and Quality Management and Temporomandibular disorders and atypical facial pain: from diagnosis to multidisciplinary management (University of Bari ALDO MORO, Italy). Laboratory Head at Department of Dental Sciences and Surgery (2009-2012). Visiting Professor at "City Unity College - Greece" (and affiliated Institutions). Visiting Scientist at "Tecnologica Research Institute" in Crotone, Italy. Member of the " World Academy of Growth Factors & Stem Cells in Dentistry- WAGroFSCD". Author of scientific papers and book chapters on National and International Journals (and Books) with Impact factor. Winner of "Research Award" from Medical and Dental Council of Bari (Italy) in year 2016. Winner of “Sant’Apollonia Award” from ANDI (Italian Dental National Association) in year 2005 for the best clinical and scientific report in Dental Sciences. Invited reviewer, Lead Guest Editor, Past-Associate Editor and Editorial Board Member in International Journals. Lead Guest Editor for "Stem Cells International" http://www.hindawi.com/journals/sci/si/523172/cfp/ (Published/Hosted by: Hindawi Publishing Corporation). In 2015 and 2017 Principal Investigator (PI) in the INNBIORESTM RESEARCH INCENTIVE AWARD, founded from “Innovative-Biological-Research Center”. Participant in European Research Projects Industry-Academia Partnerships and Pathways (IAPP)- FP7-PEOPLE-2012-IAPP “LUSTRE”- Ultra-fast Laser Surfacing of Teeth for Resistance to Erosion. (grant from 2014-01-01 to 2017-12-31- submission phase- Project reference: 324538). Participant in Research Projects of National interest on Stem Cells isolation, differentiation and clinical application, funded by the Ministry of University and Scientific and Technological Research (MIUR) (grant 2002 for the biennium 2002-2004, grant 2005 for the biennium 2005-2007, grant 2007 for the biennium 2008-2010, grant 2009 for the biennium 2011-2013). Participant in various Research Projects founded from University of Bari ALDO MORO and Local Foundation (Fondazione Cassa di Risparmio di Puglia). Invited speaker in National and International courses and conferences.

Scientific research activity in Dentistry, Stem Cells, Sexual Transmitted Diseases, Medical Genetics, Clinical Biochemistry, Dermatology, Immunology, Microbiology, Public Health and Preventive Medicine, Maxillofacial Surgery, Biotechnology, Occupational Medicine, Sleep Medicine, Biochemistry and Dental Hygiene. Actually the research lines are focused on: stem cells from oral and extra-oral tissues, regenerative therapies in dentistry and maxillofacial surgery, biomimetic scaffolds, genetic disorders with and without oral and maxillofacial features, genetics of periodontal disease and its correlation with systemic diseases, genotoxicity, cytogenetic, biochemistry implant dentistry, orthodontics, and Laser Technology and Therapy.

Dr. Juan F. Santibanez received his PhD from the Instituto de Investigaciones Biomédicas “Alberto Sols” (IIBM), Spain in 1999, worked as a postdoctoral fellow at the “Centro de Investigaciones Biologicas, CIB”, Spain from 2003 to 2005. Dr. Santibanez was Associated Research (1991 to 1995), Instructor (-1999) and Assistant Professor (-2008) at the Laboratory for Cellular Research, INTA, Universidad de Chile. He is currently a Professor of Research at the Institute for Medical Research (IMI), Belgrade, Serbia.

His major research area is the role of TGF-in tumor invasion and progression, and inflammatory factors in mesenchymal stem cells biology. Recently has been become interested in role of myeloid-derived suppressor cells (MDSC) in myeloproliferative neoplasm.

2015, Emory STEM Research and Career Symposium, Atlanta, GA - Judges Committee 2015, Society for Developmental Biology 74th Annual meeting, Snowbird, UT - Poster Judge 2015, North American Vascular Biology Organization (NAVBO), Vascular Biology, Hyannis, MA - Poster Judge 2016, Emory STEM Research and Career Symposium, Atlanta, GA - Judges Committee 2017, IACUC Committee, Emory University (Alternate since July 2017)

The establishment of the cardiovascular system including blood, vasculature and the heart is a highly coordinated process and a prerequisite for embryonic development. A failure of proper development in any of these cell lineages leads to fetal death, stillbirth or life-threatening birth defects. Further, the cardiovascular system is an indispensable organ to maintain one’s daily life, and abnormality of it is salient in the pathogenesis of diseases and/or defects such as congenital heart disease and cancer. Congenital heart disease (CHD) is a defect, or abnormality of the heart or blood vessels associated with the heart and is the most common, afflicting one in 100 live births. Not only in adults, another leading life-threatening disease in childhood is cancer; brain and central nervous system tumors, neuroblastoma and Wilms tumor consist of approximately 33% of childhood cancer. Tumor growth and survival are critically dependent upon non-physiological vessel formation. Thus, therapeutic strategies for treating cardiovascular defects and diseases related to dysfunctional vessels should be in the establishment of the functional cardiovascular system that is tightly and delicately coordinated by a series of genetic and epigenetic regulations in developing fetuses. The major effort of the PI’s team is to decipher the underlying mechanisms as to the successful generation of the cardiovascular constituents, namely endothelial, endocardium, cardiomyocytes and hematopoietic cells that share multipotent cardiovascular progenitors, FLK1+ cells. In this regards, we previously reported that ETV2/ER71, a new member of the ETS transcription factor family, is the direct upstream regulator of VEGFR2 (Vascular Endothelial Growth Factor 2, also known as FLK1) and that ETV2 is indispensable for cardiovascular system development. Extending from the previous findings, our significant effort is currently given to study molecular mechanisms by which ETV2 regulates cardiovascular system development. In addition, my lab is interested in the generation of functional endothelial cells directly from somatic cells such as skin fibroblasts (direct reprogramming), aiming autologous cell replacement therapy. Outcome from these studies will provide a new and detailed insight into cardiovascular development, which could provide novel opportunities for the development of specific targets for the cardiovascular defects/diseases.

Govindan Dayanithi, born 1st July 1956, was educated in India (The University of Madras; 1972-1983) as a Biologist, Zoologist, Parasitologist (Experimental parasitology: Fasciolosis and Echinococcosis, Epidemiologist; Comparative Anatomy & Physiologist and Crustacean Endocrinologist. He came to Europe in 1983 as a French Ministry of Education Post-Doctoral Fellow (CROUS), followed by a fellow of French Medical Foundation (FRM-France, 1985) and a fellow of the Alexander von Humboldt Stiftung (Germany, 1987-1990). In addition, he was appointed as “Chargé de Recherche” at the Faculty of Medicine (Centre de Neurochimie, 1987)-University of Strasbourg and as Senior Research Assistant at the Department of Anatomy-University of Oxford (1987-1989) before being permanently employed by the French Ministry of Research (CNRS) as “Chargé de Recherche-CR1” (1990) and then promoted as “Directeur de Recherche” (since 1997). In the following years, he was awarded the Japanese Society for Promotion of Science Invitation Fellowship (2004, 2008, 2011, 2014) to conduct research and teaching activities in several Japanese universities and research institutions (Kitakyushu, Kyoto, Jichi, Sapporo, Osaka). Simultaneously, he has been collaborating with British (Oxford, Edinburgh, Manchester, Birmingham (since 1997) and US research institutions (Worster Foundation, UMASS Medical School, NIH (since 1987). He has been teaching at the university of Madras and continuing to dedicate to his major commitments to fulfill his Ph.D program (1978-1982); and followed his teaching and research activities in several institutions (Oxford, Ulm, Bordeaux, Montpellier, Marseille, Rouen, Strasbourg, Prague, Plzen, Hradec Kralove, Usti nad Labum). He is a multi-lingual person who lived personally and scientifically in India, France, Germany, Belgium, Hungary, Poland, Czech Republic, Italy, UK, USA and Japan. He was then appointed as ‘Charge de Mission Europennes et Internationales’ at the CNRS Delegation office in Montpellier (1999-2002) followed by a long-term scientific mission as ‘French scientific expert’ at the European Commission (Brussels; 2002-2006), and then was authorized to continue his scientific mission at the Institute of Experimental Medicine of the Academy of Sciences of the Czech Republic, an EU Centre of Excellence in Prague (2008-2011). He was then permitted to continue his collaborative research and teaching activities between France, Czech Republic, UK, Japan and USA. Since April 2012, he has been appointed at the INSERM unit 170 followed by U1198 at the University of Montpellier and at the Ecole Pratique des Hautes Etudes-Sorbonne. During this period, he has been authorized to conduct research on ‘special Mission’ at foreign institutions. Recently, since October 2016, he has been also appointed as Professor at the Faculty of Pharmacy of the Charles University at Plzen-CZ. Further, he serves as an Editorial Board member/associate Editor of the Cell Calcium, International Journal of Cell Biology, The Scientific World Journal, The IIOAB Journal and Frontiers in Stem Cell Research. He is a consistent and constant expert reviewer for many journals; and is a multi-disciplinary expert in various EU research programs who has published more than 125 papers in various peer-reviewed journals. He wrote one book with his PhD student and currently editing another Master Class in Neuroendocrinology Series. Book title: “Neurosecretion: Secretory Mechanisms; Publisher: Springer NATURE ); which is due in January 2018. His major research focus on i) the physiology of calcium signalling in excitable and non-excitable cells ii) stimulus-secretion-coupling at the level of neurohypophysial system, iii) physiopathology of central and peripheral vasopressin and oxytocin; iii) exocytosis, iv) calcium signalling mechanisms/homeostasis in central and peripheral nervous system tissues and v) ion channels and receptors and calcium signalling signalling mechanisms Stem Cell of different origin and different experimental conditions and, vi)) pathophysiology of calcium signalling in stem cells (sk-DMSC & bone marrow) from non-human primate animal model (Microcebus murinus) for Alzheimer’s and Parkinson disease.

1) Stimulus-secretion-coupling 2) Molecular physiology of calcium signalling in the CNS and PNS neurons 4) The physiology of vasopressin and oxytocin signalling in nociception, pregnancy and lactation 5) The physiology of calcium signalling in human embryonic stem cell-derived neuronal precursors 6) Calcium imaging and neuron-glia interactions in neurodegerative diseases (ALS and AD)

• 2004-2006 Computational Biology Research Center, AIST (Post-doc fellow) • 2006-2009 Sony Computer Science Laboratories, Inc. (Post-doc fellow) • 2009-2018 Sony Computer Science Laboratories, Inc. (Associate Researcher)

Medical Sciences, Information Sciences, etc

I am an active researcher in the areas of Clinical Biochemistry, Molecular Biology, and Cancer Stem Cell Biology. My innovated research focus on discovery new methods, techniques and new treatment strategies for different Metastatic cancers. In doing so, I envision a world where knowledge is continually harnessed to drive new value and support sustainable growth and enhance the life quality of the cancer patients. In Egypt, I established the state-of-the-art cancer research laboratory in 2010 at Alexandria University, focusing on isolation, culture, gene manipulation of Cancer Stem Cells vs human Cancer cells as a new strategy for cancer treatments.

1-Biochemistry and molecular biology 2-Gene therapy and stem cell technology in cancer treatment. 3-Signal transduction in cancer molecular biology. 4-Genetically engineered animal models for breast and liver cancer. 5-Anti-cancer drug delivery: using new vehicle for carrying drugs ("Bioreactor") and its potential clinical application to get rid of excessive blood urea in patients with breast and liver cancer.

Dr. Jyoti Bhojwani, is presently a Faculty of Genetics/Bioinformatics/ Principal Investigator of the M.Tech Research Programs (Bio-Informatics) at University of Indore, India. She obtained her B.Sc.(Bachelors degree) in Biological Sciences/Chemistry/Physics, M.Sc.(Master’s degree) in Life-Sciences, and Doctoral degree (Ph.D.) at School of Life-Sciences, University Of Indore. She pursued her post-doctoral ventures at Max-Planck Institute For Biophysical Chemistry (FRG), University Of California-Irvine and University Of Pittsburgh (USA). Currently, her projects mainly focus on translational-research and extrapolation of basic developmental mechanisms from model-systems like fruitfly (Drosophila) to human. Apart from this, her thrust areas of research interest include; Cancer Biology, Stem-Cell Biology and Homeotic-Gene Regulation. She is keen on studying in details the genetic factors, which presumably aid in understanding of mechanism by which “cancer stem cells” function in transforming a tissue from normal to cancerous states.

Her research has a motive to further facilitate the perception of stem cell potential/mechanistic in areas of Regenerative Medicine, Translational Research and Anti-cancer therapy. Being involved in Clinical informatics, her students are also training a Cancer model and a Stem cell model, deploying Systems Biology approach and other Gene Networking Bio-Informatics tools. This novel area of research will hopefully lead to further understanding the tipping of balance from a stem cell/normal cell to a transformed cancer cell. Owing to her immense interest in science journalism and writing potential, she is now on the editorial board of several International Journals. Her Specialties Include: Research/Teaching/Mentoring/Science-Journalism

Mahmoud Abd-Elkareem Mahmoud Mohamed, (Ph.D. in histology, 2014) is serving as a Lecturer of histology at Anatomy, Histology and embryology department of Faculty of Veterinary Medicine, Assiut University, Assiut, Egypt. In his M.S.C thesis, he discussed the histomorphological developmental changes of the rabbits ovary during the postnatal period, while in Ph.D thesis he described the histomorphological changes of the rabbits ovary during pregnancy and pseudopregnancy. Experienced in histological and cytological techniques. He has several scientific publications both in local and international peer-reviewed and high impacted journals and worked as a reviewer in a number of medical journals. Member of the Quality Assurance and Accreditation project, Faculty of Veterinary Medicine, Assiut University (2009-2013). He is also A member of the Quality Assurance Unite, Faculty of Veterinary Medicine, Assiut University from 2014 till now.

Histology, cytology, reproductive biology, development of the ovary, histo-pathology, immunohistochemistry, immunocytochemistry, Frozen section,.

MinYoung Kim is currently professor and director of Department of Rehabilitation Medicine and Rehabilitation and Regeneration Research Center, CHA University, Korea. She graduated Yonsei University College of Medicine, Seoul, Korea at 1991. She obtained the degree of Doctor of Medical Science in 2002 and worked in Neurosciences department of UC San Diego as post-doctoral fellowship. She published many articles of SCI and Pubmed journals about clinical and translational research for brain dysfunction and recovery. She is serving Korean Academy of Pediatric Rehabilitation and Developmental Medicine Society as Chairman of the Board, and has actively participated as reviewer in many medical science journal. Her main research interest field is "Development of neuroregenerative technology including stem cell therapy for brain diseases".

Stem Cell Therapy and Regenerative Medicine for Brain Dysfunction Including Cerebral Palsy Brain Rehabilitation & Health Care Using Information and Telecommunications Technologies Cognitive Training

Head of the Faculty of biomedical engineering. Islamic Azad University Tehran Central Branch

• Tissue mechanics & Stem cells • Heat Transfer • Bio-fluids • Mircofluidics

He completed his PhD doctorate at Mount Sinai School of Medicine in New York City. His fellowship experience includes the Massachusetts Institute of Technology/Whitehead Institute (NIH-Individual National Research Service Award) and Harvard University Medical School. He serves as principal investigator (Faculty Scientist) at CHOC Children’s Hospital Research Institute/University of California-Irvine School of Medicine, and adjunct professor of California State University Fullerton and Sun Yat-sen University. He has 154+ publications and 20 U.S.-issued patents. His work is remarked in articles published in Nature, Science, Cell, Nature Review Cancer, Nature Review Medicine, Annual Reviews of Cell and Developmental Biology, with citations of 7,938+ (single-papers with ~ 1000 citations). He serves on editorial board of Journals (Am. J. Pathol., Curr. Stem Cell Res. & Ther., World J. Stem Cells) and with membership of ACTS, ISSCR, SfN, ASCB, ASN, ASIP, RSM (elected overseas fellow).

Cancer, Cancer Stem Cell, Ipsc, Brain Tumor, Matrix Scaffold For Culture Of Stem Cells, Ex Vivo Model, In Vitro, In Vivo Model, Clinical Oncology, Single-Cell Transcriptome For Subclonal Evolution Of Cancer, Signal Transduction In Cancer, Immunotherapy, Tumor Microenvironment.

Osama M. Ahmed, (born in November 24, 1970) is a professor of physiology at Faculty of Science, Beni-Suef University and Faculty of Oral and Dental Medicine, Nahda University, Beni-Suef, Egypt. He has granted Ph. D. in Physiology from Faculty of Science, Cairo University, Egypt at year 2000. He holds more than 90 publications in the fields of his expertise in international journals. He has written two book chapters titled "Recent Advances in Chemistry and Biology of Natural Products" and "a New Look Hypothyroidism". He is an editorial board member in more than 25 international journals. He was awarded the State Incentive Prize (2014), Beni-Suef University Excellence Prize (2014) and the state excellence honor of the first class (2017). He is principal investigator and co-principal investigator in many research projects.

He holds more than 90 publications in the fields of his expertise in international journals. He has written two book chapters titled "Recent Advances in Chemistry and Biology of Natural Products" and "a New Look Hypothyroidism".

I am a professor of molecular cell biology in Zoology Department, Faculty of Science, Beni-Suef University, Egypt, having 50 publications in national and international journals and supervised 24 Master and Ph. D Thesis. I attended many conferences and special and general training workshops.

My research focus on exploring the toxic effects of some food additives and nano-materials, the use of stem cells and natural products in treatment of certain diseases such as diabetic wounds, epilepsy, cancer, osteoporosis, diabetes, hypo- and hyperthyrodism, Rehumatoid arthritis, liver failure.....etc in different experimentally-induced models. Different tested markers and activity of the tested natural products were carried out using cytotoxicity tests, anti-tumour activity, cell death detection (apoptosis and necrosis), PCR, Gel-electrophoresis, immunohistochemistry, ultrastructure and histopathological changes in addition to cell cycle stages.

Holds a degree in Biological Sciences and Pharmacy, in addition to specialization in Clinical Analysis by the Federal University. He holds a PhD in biochemistry (IQ-USP), holds a postdoctoral degree in biophysics and another in physics in the application and production of nanomaterials for nanobiotechnology. Has H 32 factor, google school, experience in the field of General Biology, with emphasis on Neurosciences, Nanobiotechnology, Stem Cells, Calcium Signaling, Tissue Engineering, Molecular Biology, Nanocircuits and Neural Networks. He is currently an associate professor in the Department of Biochemistry and Immunology at ICB / UFMG. Advisor to the Graduate Program in Biochemistry and Immunology (Capes 7) and PG in Cell Biology (Capes 6) and PG in Bioinformatics (Capes 7). Co-founder and founder of the master's degree in Biotechnology at UFSJ-CCO. Scientific Editor of Cell Communication and Signaling (FI 5.5), Associate Editor Frontiers in Cell and Developmental Biology, World Journal of Cell Stem Cells, Calcium Signaling, Current Pharmaceutical Design, Seminars in Cell and Developmental Biology (6.6) and others. Founder and creator of the Nanocell News Scientific Newspaper with more than 300 thousand subscribers, 1 MILLION of accesses MONTH, http://www.institutonanocell.org.br/ and more than 40 thousand and 18 thousand followers in Facebook in two pages. He is the author of more than 300 articles of this newspaper, according to its norms. Founder with 46 other scientists from around the world (President of the first board) of the Brazilian Society of Cellular Signaling (SBSC).

Cell Stem Cells, Calcium Signaling, Current Pharmaceutical Design, Cell and Developmental Biology.

Caterina Pipino is a postdoctoral fellow at the Vascular and Stem Cell Biology lab of the University of Chieti-Pescara, directed by Professor Assunta Pandolfi. She earned her Master’s degree in Pharmaceutical Chemistry (2008) and her Ph.D. in Biomedical Science (2013) at the University of Chieti. During her PhD she spent 18 months at University College of London in the laboratory of Stem Cells and Regenerative medicine directed by Dr. Paolo De Coppi. The primary long-term goal of her research is focused on stem cells and tissue engineering by trying to find new modalities for the treatment of bone-related diseases. She is specifically focused on perinatal stem cells, such as amniotic fluid stem cells, as an innovative source that could be stored in banks and used for therapies and in research, a viable alternative to the limited embryonic stem cells. She is also interested in generating induced Pluripotent Stem Cells as an in vitro model to study the mechanism of disease and test new drugs.

Aligned with her interests in stem cell biology is the study of vascular complications associated with diabetes using various cellular models. Currently, she is working at Joslin Diabetes Center, a Harvard Medical School affiliate, carrying out a collaborative project.

Prof. Dr. Alireza Heidari, Ph.D., D.Sc. is a Full Professor and Academic Tenure of Chemistry at California South University (CSU), Irvine, California, USA. He has got his Ph.D. and D.Sc. degrees from California South University (CSU), Irvine, California, USA. Furthermore, he has double postdocs in Project Management, Oncology, Human Cancer Tissues and Synchrotron Radiation from Monash University, Melbourne, Victoria, Australia and also in Nanochemistry and Modern Molecular Electronic–Structure Computations Theory from California South University (CSU), Irvine, California, USA.

His research interests include Biophysical Chemistry, Biomolecular Spectroscopy, Quantum Chemistry, Nanochemistry, Modern Electronic Structure Computations, Theoretical Chemistry, Mathematical Chemistry, Computational Chemistry, Vibrational Spectroscopy, Molecular Modelling, Ab initio & Density Functional Methods, Molecular Structure, Biochemistry, Molecular Simulation, Pharmaceutical Chemistry, Medicinal Chemistry, Oncology, Synchrotron Radiation, Synchrocyclotron Radiation, LASER, Anti–Cancer Nano Drugs, Nano Drugs Delivery, ATR–FTIR Spectroscopy, Raman Spectroscopy, Intelligent Molecules, Molecular Dynamics, Biosensors, Biomarkers, Molecular Diagnostics, Numerical Chemistry, Nucleic Acids, DNA/RNA Monitoring, DNA/RNA Hypermethylation & Hypomethylation, Human Cancer Tissues, Human Cancer Cells, Tumors, Cancer Tissues, Cancer Cells, etc.

2010 MD (PATHOLOGY) - KMC Medical College, Manipal 2006 MBBS - MGM Medical College, Jamshedpur (Ranchi University) Gold MEDAL in Physiology, Pharmacology and Pediatric PROFESSIONAL EXPERIENCE 2013-Till Date Government Medical College, Kota, Rajasthan Assistant Professor 2011-2013 Apollo Hospital, Bhubaneswar Senior Registrar, Department of Pathology 2010-2011 Rajiv Gandhi Cancer Hospital and Research Centre, New Delhi

Oncopathology, pap smear, cytology, IHC and hematology. In oncopathology subspeciality includes breast, head and neck, urology and gynaecologic cancer.

Dr. Nadeem Kizilbash received his Ph.D. in Biophysics from Boston University (USA) in 2003. His doctoral thesis was titled: “Biophysical Studies of Fatty Acid Binding Proteins and Hydrophobic Ligands”. He completed a postdoctoral fellowship at Penn State University (USA) and is presently serving as Head & Assistant Professor of Biochemistry at Northern Border University (Saudi Arabia). He has published a monograph in 2013 and is the author of more than 40 international publications in the areas of Structural Biology, Protein Chemistry, Drug Delivery, Gene Polymorphism, Oncology, Endocrinology, Toxicology and Medicinal Chemistry.

Dr. Kizilbash is serving on the editorial boards of various journals. He has experience in conducting both basic and clinical research. He has published research papers in the areas of Structural Biology, Protein Chemistry, Drug Delivery, Gene Polymorphism, Toxicology, Parasitology and Synthetic Organic Chemistry.

A total work experience of nearly 18 years in teaching, research, academia, industry, product development, business development and regulatory affairs in the field of Biotechnology. My experience has provided me a holistic understanding of almost all the aspects of Biotechnology. Working with the stalwarts has indeed been the most enriching and a rewarding experience as it has provided me an opportunity to continuously learn, nurture and evolve myself as a professional and an individual.

 Assistant Prof, Department of Biotechnology, Uttaranchal University, Dehradun from 01th June 2017. Job Responsibility: • Teaching Subject fermentation technology, cell biology and Recombinant DNA Technology. • Research and Development • University Paper Setter.  Assistant Prof, Department of Food Science & Technology, Khalsa College, Amritsar from 01st August 2016 to May 2017 Responsibility: • Teaching subjects – Fermentation technology, Biochemistry, Industrial microbiology, Food Biotechnology. • Research and Development –Utilization of food waste and waste biomass for treatment of waste water & production of energy. • University Paper Evaluator

( Biomass to Biogas ,Wastewater treatment, solid waste management)

Nidhi Gupta has expertise across a wide range of cutting-edge genomics technologies and experience in developing research applications. She is highly motivated and passionate about integrating new methods and technologies into anti-biotic resistance research and diagnostics. She has more than 10 years of experience in genomics, biotechnology and biomedical sciences. Currently she is leading the molecular biology team at Shield Diagnostics as Director of Molecular Biology. She recently led a team to develop and launch an LDT product for diagnosis of gonorrhea resistance. Prior to joining Shield Diagnostics, she worked in a start-up company developing microarray based platforms for sequencing. She initiated and configured several sections of lab facilities for the company. She spent more than 2 years at Harvard Medical School to study cell signaling and insulin resistance. She earned her B.S. in Human Genomics with minor in Biomedical Sciences at NCHGSR, India and PhD in Genetics and Developmental Biology at UCHC, Connecticut. During her PhD, she developed a novel mechanism for targeted mitochondria delivery to hepatocytes. She was also involved in various other viral studies and successfully developed small RNA sequences for HCV replication inhibition. She authored and co-authored many articles and patents involving mitochondria replacement therapies and HCV treatment.

Anti-biotic resistance, sepsis, sexually transmitted diseases, sequencing and genomic technologies

Dr. Fuliang Du was graduated as a Ph.D. in the major of Genetics and Molecular Biology at Cornell University in Ithaca, New York in 2000. Dr. Du has a strong research interest of molecular reprogramming and epigenetic regulatory mechanism of nuclear transfer and embryonic stem cells. Dr. Du’s team has also performed the studies of gene knockout/genetic modification using transgenic animal models for biomedical research, reproduction by in vitro maturation/fertilization/culture, preimplantation embryo development and its gene expression/regulation. Dr. Du has published more than 70 scientific papers, and provided numerous seminars on international academic conferences. Dr. Du had been supported with research funds from US National Institutes of Health (NIH) and U.S. Department of Agriculture (USDA) when he was worked in USA.

Since 2012, Dr. Du has worked as a tenured full professor in the College of Life Sciences at Nanjing Normal University, where he has established the center for transgenic animal research, and the laboratory of translational genomics and embryology.

Born May 1938 Studies in Paris Now Professor Emeritus Lab Sciences fondamentales et médicales- University Paris cité- Paris 5

Research Interest: odontogensis, amelogenesis, dentinogenesis, dental pulp, stem cells,

• Worked as Lecturer in Department of Biotechnology, Kumaraguru College of Technology, Coimbatore from 1-11-2004 to 18-5-2005. • Worked as Lecturer in PG Department of Biotechnology, SNMV CAS, Coimbatore from 1-6-2005 to 2-6-2007. • Worked as Lecturer in School of Biotechnology, Dr.G.R.D. College of Science, Coimbatore from 9-6-2007 to 30-4-2008. • Research experience for pursuing Ph.D under the guidance of Prof.P.K.Paul, Deputy Director, Amity Institute of Biotechnology from May 2008 to November 2012. • Currently working in PG & Research Department of Biotechnology, Kongunadu Arts and Science College, Coimbatore since 10-07-2013.

Plant Molecular Biology and Recombinant DNA Technology

Cecilia E. Van Cauwenberghe received his bachelor degree in chemical engineering and modern physics with honors from The National University of Comahue, Argentina. She later earned her Ph.D. in chemical engineering and M.Sc. in biomedical engineering from The Favaloro University, Argentina, studying with Dr. Ricardo Luis Armentano Feijoo. She completed postdoctoral work in Technology and Innovation Management at The National University of Tres de Febrero, Argentina. Dr. Van Cauwenberghe also perfected her knowledge in Europe, modestly contributing to biomedical and biochemical modeling and simulation in both academia and industry. Dr. Van Cauwenberghe joined the TechVision (formerly Technical Insights) group of Frost & Sullivan in 2010, to track and analyze emerging trends and cutting-edge medicine technologies, also highlighting opportunities for partnering and capital attraction, in addition to promote the technology translation of biomedical innovations to the industry and the clinic.

Biochemistry, Bioengineering, Biomolecules, Clinical Medicine, Delivery of Screening Tests, Drug Design, Development and Therapy, Epidemiologic Studies, Health Informatics, Immuno Targets and Therapy, Immunology, Infectious Diseases, Molecular Diagnostics, Molecular Modeling, Nuclear Medicine, Pathogenesis of Disease, Pharmacodynamics, Pharmacokinetics, Pharmacology, Proteomics.

Laila Montaser, is Professor of Clinical Pathology, Chair Stem Cell, Regenerative Medicine, Nanotechnology and Tissue Engineering (SRNT) Group, serves as the President, Founder of Clinical Pathology Department, Faculty of Medicine, Menoufia University, Egypt. She gained 4 Awards: - Gold Nishan perfect of merit and distinction and Certificate of Excellence for the best pupil in Alexandria Governorate from Egyptian Feast of Science. - Medal of Merit from Egyptian Medical Syndicate nominated from Menoufia Faculty of Medicine Council in 1986, 1998, & 2002. She supervised more than 44 M. Sc. theses and 12 Doctorate theses.

She is uniquely trained and situated and has a philosophy on how to manage research specifically with Stem Cell, Regenerative Medicine, Nano medicine and Tissue Engineering, her research interest.

Yoon Young Kim, (born Nov 28 th 1977) is a research professor of Department of Obstetrics and Gynecology from Seoul National University Hospital, serving since 2015. Her branch of knowledge is reprod uc tive medicine, particula rly in the spheres of “stem cell Biology” “Stem cell therapy ””, a nd “reproductive She received her PhD from Seoul National University College of Medicine, Seoul, South Korea in 2006 and received postdoctoral research fellow training in Institute of Reproductive Medicine and Population of Seoul National University of Seoul National University. Yoon Young Kim published about 50 original peer reviewed a rticles, and 140 abstracts presented at scientific conferences. Yoon Young Kim‘s research has been continuously funded by the National Research Foundation NRF , South Korea ) since 20 10. She served as Editorial board member of Tissue Engineering and Regenerative Medicine (Electronic ISSN 2212 5469) since 2015.

She is interested in “stem cell establishment/differentiation” and “stem cell therapy for female reproductive track”, especially p roduction of artificial ovary with stem cel ls and development of therapeutic strategies for uterine disease using tissue engineering. Recently, she also focused on the development of non human primate model for female reproductive track (FRT).